MedDataX Logo

Safety and Efficacy of AGN 203818 for Pain Associated With Fibromyalgia Syndrome

NCT ID: NCT00445705

Last Updated: 2015-09-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

211 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with fibromyalgia syndrome. The study is being conducted in 2 parts. Part A enrolled 211 pts dosed with either 3, 20, 60 mg BID AGN 203818 or placebo over 4 week treatment duration. Part B will enroll 440 pts and dose with either 20, 100, 160 mg BID AGN 203818 or placebo over 12 week treatment duration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Pain Associated With Fibromyalgia

NCT02187159

Pain Associated With Fibromyalgia
COMPLETED PHASE3

Treatment of Pain Associated With Fibromyalgia

NCT02187471

Pain Associated With Fibromyalgia
COMPLETED PHASE3

The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.

NCT00464737

Fibromyalgia Syndrome
COMPLETED PHASE2

A Study for Adolescents With Fibromyalgia Syndrome

NCT01089621

Fibromyalgia
WITHDRAWN PHASE4

Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

NCT06411067

Fibromyalgia
WITHDRAWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fibromyalgia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Part A: Placebo every 12 hours for 4 weeks

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Part A: Placebo every 12 hours for 4 weeks

AGN 203818 3 mg

Part A: 3 mg AGN 203818 every 12 hours for 4 weeks

Group Type EXPERIMENTAL

AGN 203818

Intervention Type DRUG

Part A: AGN 203818 3 mg every 12 hours for 4 weeks

AGN 203818 20 mg

Part A: 20 mg AGN 203818 every 12 hours for 4 weeks

Group Type EXPERIMENTAL

AGN 203818

Intervention Type DRUG

Part A: AGN 203818 20 mg every 12 hours for 4 weeks

AGN 203818 60 mg

Part A: 60 mg AGN 203818 every 12 hours for 4 weeks

Group Type EXPERIMENTAL

AGN 203818

Intervention Type DRUG

Part A: AGN 203818 60 mg every 12 hours for 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

Part A: Placebo every 12 hours for 4 weeks

Intervention Type DRUG

AGN 203818

Part A: AGN 203818 3 mg every 12 hours for 4 weeks

Intervention Type DRUG

AGN 203818

Part A: AGN 203818 20 mg every 12 hours for 4 weeks

Intervention Type DRUG

AGN 203818

Part A: AGN 203818 60 mg every 12 hours for 4 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of fibromyalgia syndrome
* Moderate or severe pain associated with fibromyalgia

Exclusion Criteria

* Any other uncontrolled disease
* Pregnant or nursing females
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Allergan

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Canton, Ohio, United States

Site Status

Geneva, , Switzerland

Site Status

Stanmore, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

203818-503

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
NCT03056690 COMPLETED PHASE2
Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia
NCT00830167 COMPLETED PHASE3
A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.
NCT00423813 COMPLETED PHASE3
Duloxetine Versus Placebo for Fibromyalgia
NCT00489073 COMPLETED PHASE3
Fibromyalgia and Naltrexone: The FINAL Study
NCT04270877 COMPLETED PHASE2
Effectiveness of the Sana Device on Fibromyalgia Symptoms
NCT05394610 NOT_YET_RECRUITING NA
Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia
NCT00754221 TERMINATED PHASE3
A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia
NCT00357825 COMPLETED PHASE2
A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.
NCT00612170 COMPLETED PHASE3
The Effect of Sympathetic Dysfunction on Muscle Spindle in Fibromyalgia
NCT05704374 UNKNOWN NA
A Study of Duloxetine in Fibromyalgia
NCT01552057 COMPLETED PHASE3
Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?
NCT02806440 COMPLETED PHASE4
A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia
NCT04974359 TERMINATED PHASE1
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
NCT01271933 COMPLETED PHASE3
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
NCT04147858 COMPLETED PHASE2
A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome
NCT01237587 COMPLETED PHASE3
Gabapentin in Fibromyalgia Trial (GIFT)
NCT00057278 COMPLETED PHASE2/PHASE3
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
NCT03783910 COMPLETED PHASE2
Phase 2 Study of TD-9855 to Treat Fibromyalgia
NCT01693692 COMPLETED PHASE2
Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement
NCT05718908 COMPLETED
A Study for Adult Patients With Fibromyalgia
NCT00965081 COMPLETED PHASE4
The Effect of Minocycline and N-acetylcysteine for the Treatment of Fibromyalgia
NCT04594733 COMPLETED PHASE1/PHASE2
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
NCT02234583 COMPLETED PHASE3
Trial Comparing the Effects of Xyrem (Sodium Oxybate) With Placebo for the Treatment of Fibromyalgia
NCT00087555 COMPLETED PHASE2
Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
NCT00190866 COMPLETED PHASE3